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culture-positive endocarditis. In-hospital clinical course, the need for surgery
and mortality are similar to those in patients with blood culture-positive endo-
carditis.
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Embolic complications (EC) occur in about 30% to 40% of left-sided
infective endocarditis (LSIE) and are associated with a poor prognosis. We
analysed risk factors for embolic events in the systematic analysis of a large
cohort of consecutive patients treated for infective endocarditis (IE).
Methods: 533 consecutive patients admitted for definite or probable LSIE
were included in this study.
Results: Mean age was 64 and 26% had a prosthetic valve. The loca-
tion of IE was aortic in 68%. Causative microorganisms were Streptococ-
caceae in 40% and Staphylococcaceae in 27%. Rate of valve surgery and
mortality during the initial hospital stay were 26% and 11%, respectively.
The mean follow up was 5±6 years. Embolic events occur in 164 patients
(30%). In multivariate analysis, presence of vegetation was an independent
risk factor for embolic event (hazard ratio HR=1.96, p<0.001), whilst older
age and Streptococcus infection were independently associated with a
lower risk of embolic events (HR=0.99, p=0.02 and HR=0.64, p=0.02
respectively). 
Conclusions: Patients with LSIE and streptococcal infection have a lower
risk of embolic events than others. The presence of vegetations was indepen-
dently associated with an increased risk of embolic events. 
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Background: The PROTECT AF trial previously demonstrated that left
atrial appendage closure (LAAC) was non inferior to warfarin in patients with
nonvalvular atrial fibrillation (NVAF). However, this trial included patients
eligible for anticoagulation therapy who received warfarin for 6 weeks after
device implantation. The purpose of the present study was to assess the safety
and efficacy of LAAC for stroke patients with NVAF and contraindication for
anticoagulation. 
Methods: Consecutive patients with a previous ischemic or hemor-
rhagic stroke, NVAF and contraindication for anticoagulation underwent
LAAC with the Amplatzer Cardiac Plug device between July 2010 and
July 2013 in a French university hospital. Follow-up included clinical
evaluation at 3 and 12 months, and a cardiac computed tomography (CT)
at 3 months. Single-antiplatelet therapy was prescribed after the procedure
for a minimum of 3 months and stopped if the control cardiac CT demon-
strated complete LAA exclusion. RESULTS: 26 patients (age 73±8 years)
were included. The mean CHA2DS2-VASc and HAS-BLED scores were
4±1.5 and 4±0.8, respectively. The main contraindications for anticoagula-
tion were: intracerebral hemorrhage while receiving anticoagulation
(62%), ischemic stroke with large hemorrhagic transformation (15%) and
probable cerebral amyloid angiopathy (8%). The procedure was successful
in 100%. Procedure-related complications were serious pericardial effu-
sion (3.8%) and femoral bleeding (7.7%). During a mean follow-up of 8.6
(3-16) months, ischemic stroke occurred in 2 patients (7.7%), after anti-
platelet therapy was stopped for one of them. One patient died of an intra-
cranial hemorrhage. 
Conclusion: LAAC followed by a single antiplatelet therapy could be a
reasonable alternative for stroke patients with NVAF and contraindication for
anticoagulation. Lifelong rather than short-term single antiplatelet therapy
should be prescribed after the procedure for patients at high cardio-vascular
risk.
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Background: Behcet's disease is a multisystem disorder and classified as
« vasculitic syndrome with a wide variety of clinical manifestations. » Cardiac
involvement is very rare but can occur with different presentations.
Objective: To analyze the clinical characteristics of Behcet's disease with
cardiac involvement.
Methods: Patients diagnosed as Behcet's disease with cardiac involvement
in our Hospital from 1998 to 2013 were included in this analysis. The clinical
characteristics of these patients were studied retrospectively.
Results: Eighteen cardiac manifestations observed in 13 patients with
Behçet's disease are reported. 11 (84.6%) patients were male, with a mean
(±SD) age at BD diagnosis of 34.2±9.9 years. Cardiac involvement was the
first feature of BD in 9 (69.23%) patients. Cardiac involvement included ST-
elevation myocardial infarction (4 cases, 22.22%), stable angina (1case,
5.5%), right heart failure (2 cases 11.1%), pericardial effusion (4 cases,
22.22%), intracardiac thrombus (2 cases, 11.1%), pulmonary artery hyperten-
sion (4 cases, 22.22%) (Consecutive to pulmonary embolism in three cases)
and valvular disease (mitral insufficiency) (1 case, 5.5%). After a median
follow-up of 59.73 (0-180) months, 2 patients had died (directly related to car-
diac involvement).
Conclusions: The manifestation of cardiac involvement in Behcet's disease
is various. The involvement of pulmonary artery is an independent correlative
factor of mortality. Cardiologists should always bear in mind potential threats
of (a) symptomatic cardiovascular involvement in BD. 
0275
Can we use enoxaparin in pregnant women with mechanical heart
valves?
Tounsi Ahmed (1), Abid Dorra (1), Triki Feten (1), Abid Leila (1), Akrout
Malek (1), Mallek Souad (1), Frikha Imed (2), Louati Doulira (3), Chaa-
bène Kais (3), Hentati Mourad (1), Kammoun Samir (1)
(1) CHU Hédi Chaker, Cardiologie, Sfax, Tunisie – (2) Hôpital Habib
Bourguiba, Chirurgie thoracique et cardiovasculaire, Sfax, Tunisie –
(3) CHU Hédi Chaker, Gynécologie-obstétrique, Sfax, Tunisie
No definitive recommendation is available concerning optimal anti-
thrombotic therapy in pregnant women with a mechanical heart valve. The
purpose of the current study was to evaluate the clinical results of Enoxa-
parin treatment with respect to pregnancy outcome and maternal compli-
cations. 
From 2003 to 2012, 50 pregnancies were reviewed in 42 women. The
valve replaced was mitral (n=28), aortic (n=4), and both (n=10). Enoxaparin
(100 U/kg, twice daily) was used in 25 pregnancies between 6 and 12 weeks
of gestation and close-to-term only, and coumarin derivatives were used at
other times. 25 pregnant women treated with coumarin derivatives throughout
pregnancy were compared to evaluate the safety and efficacy of Enoxaparin. 
4 mothers developed mitral valve thrombosis (2 were on LMWH and 4 on
coumarin). Hemorrhagic complications occurred in 5 patients, 2 of whom
